Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allegra-D generic

This article was originally published in The Tan Sheet

Executive Summary

Barr receives ANDA approval for the first generic version of Sanofi-Aventis' Allegra-D 12-hour tablets, (fexofenadine HCl/pseudoephedrine HCl extended release), FDA announces April 14. A launch would be "at risk" due to pending patent litigation with Sanofi-Aventis over both Allegra and Allegra-D formulations. Barr recently prevailed in a dispute with Impax, gaining 180-day exclusivity of generic Allegra-D. Sanofi-Aventis plans to launch a 24-hour formulation later this year...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel